Table 3.

Proposed additional evidence that should be included in the reassessment process.

Evidence Categories	Elements
Clinical evidence	Performance status Dose delays and dose intensity Long-term toxicity Sub-groups that may benefit less from treatments
Patient values	Patient experiences and expectations Patient-reported outcomes Caregiver inputs Quality of Life (QoL) collected using validated tools
Economic evidence	Quality adjusted life years Utility values ICER using confidential prices
Implementation & Feasibility	Disease-specific treatment maps to describe current treatment sequencing and how sequencing might change dependent of the outcome of the reassessment Resource reallocation: where would the resources be reallocated from?

Abbreviations: ICER, incremental cost-effectiveness ratio; QoL, Quality of Life.